Trial Profile

A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors With Azirkitug (ABBV-514) as a Single Agent and in Combination With Budigalimab or Bevacizumab

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 28 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ABBV-514 (Primary) ; Bevacizumab (Primary) ; Budigalimab (Primary)
Indications Adenocarcinoma; Carcinoma; Colorectal cancer; Fallopian tube cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
Sponsors AbbVie

20 May 2025 Arms increased from 4 to 14. Drug Bevacizumab added newly to the intervention. Multiple indications added newly.
20 May 2025 Planned number of patients changed from 268 to 512.
20 May 2025 Planned End Date changed from 1 May 2026 to 1 Jul 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com